Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-2301 booster versus Comirnaty BA.4/5 in healthy adults in Japan
jRCT2031230340Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ARCT-2301 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Geometric mean titer of neutralizing antibodies against SARS-CoV-2 Omicron BA.4/5 at Day 29 and Seroresponse rate of neutralizing antibodies against SARS-CoV-2 Omicron BA.4/5 at Day 29. Started Sep 2023; status: completed.
02
Drugs
ARCT-2301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230340.